Skip to main content

Table 2 Outcome measurements among patients with atopic dermatitis successfully treated with methotrexate or dupilumab

From: Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study

 

Methotrexate (n = 6)

Dupilumab (n = 11)

At start

At follow-upa

p value

At start

At follow-upa

p value

Mean (range)

Mean (range)

Mean (range)

Mean (range)

EASIb

16.8 (7.4–30.3)

2.8 (0–6.8)

0.028*

28.6 (6.2–50)

5.2 (0.3–17.5)

0.003*

POEMc

17.2 (6–27)

6.7 (0–21)

0.075

19.9 (11–28)

4.9 (0–16)

0.005*

VASc

5.7 (0.7–8.5)

2.4 (0.1–7.8)

0.028*

6.3 (0.4–10)

1.1 (0.1–3.4)

0.007*

DLQIb

18.5 (10–26)

8.7 (1–15)

0.028*

10.2 (1–25)

1.6 (0–6)

0.005*

MADRSc

14.6 (13–18)

7.3 (3–12)

0.034*

13.7 (1–50)

3.9 (0–10)

0.028*

Weightd (kg)

74.8 (60–102)

70.5 (57.7–85)

0.075

87.1 (58–123)

93.6 (65.5–136.4)

0.003*

  1. Abbreviations: EASI Eczema area severity score, POEM Patient-oriented eczema measure, VAS Visual analogue scale, DLQI Dermatology life quality index, MADRS Montgomery-Åsberg depression rating scale
  2. Significant differences marked with *. P values calculated using Wilcoxon matched-pairs sign-rank tests
  3. aFollow-up after 12 months of treatment. Some patients had shorter follow-up and some variables were missing at 12 months, but collected at 6 or 9 months of follow-up
  4. bFollow-up at 12 months (n = 16), at 9 months (n = 1)
  5. cFollow-up at 12 months (n = 16), missing value at follow-up (n = 1)
  6. dFollow-up at 12 months (n = 15), at 9 months (n = 1), at 6 months (n = 1)
Back to article page

BMC Dermatology

ISSN: 1471-5945

Contact us